Cornea

The use of topical insulin eye drops led to a successful resolution of PEDs in 9 of 11 cases in the study.

Keratopigmentation technique offers therapeutic and cosmetic applications.

At the AOA Optometry's Meeting 2023, Jonathan Etter, MD, FAAO, presented with Susan Gromacki, OD, MS, FAAO, FSLS, on the OD and MD perspectives on keratoconus and collagen crosslinking.

Jacqueline Theis, OD, FAAO, shares insights from her AOA 2023 presentation on treating neurologic dry eye.

Melissa Barnett, OD, FAAO, FSLS, FBCLA, shares insights from her AOA 2023 presentation on managing keratoconus in clinical practice.

At the AOA Optometry's Meeting 2023, Jonathan Etter, MD, FAAO, presented with Susan Gromacki, OD, MS, FAAO, FSLS, on the OD and MD perspectives on keratoconus and collagen crosslinking.

The company completed enrollment in less than 6 months from the trial commencement. The phase 3 trial results combined with the completion of the first phase 3 trial are expected to support the company’s targeted NDA submission for Epioxa by the end of 2024.

The move could result in changes to guidelines that currently prohibit cornea donations from gay or bisexual men who have had sex with another man in the last 5 years of their life. There's no indication as to whether other queer communities—such as transgender women or nonbinary donors—will be impacted.

Groundbreaking treatment for patients with bullous keratopathy approved in Japan.

Surgical interventions once disease progresses.

Zeba Syed, MD, from Wills Eye Hospital discussed their research on corneal swelling and dynamics during corneal collagen crosslinking at the 2023 ASCRS annual meeting in San Diego.

The evolution opens doors for the treatment of neurotrophic keratitis and beyond.

William Trattler, MD, sat down with Sheryl Stevenson, Group Editorial Director, Ophthalmology Times®, to discuss his presentation on progressive keratoconus in older patients with delayed corneal cross-linking treatment at the ASCRS annual meeting in San Diego.

Speaking at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Marcony Santhiago, MD, points out there are subtle differences in patients with keratoconus that was progressing compared with patients whose disease was stable and healthy control subjects.

In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Ana Balbuena-Pareja, MSc, explained how cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) had a positive effect on corneal nerve regeneration and sensation in patients with neurotrophic keratitis.

Eyecelerator kicks off today as the American Society of Cataract and Refractive Surgery will host this year’s ASCRS and ASOA Annual Meeting in San Diego, California, beginning on Friday. ViaLase Inc., Aurion Biotech among companies presenting at the annual meeting.

Jamie Kuzniar, OD, discusses scleral lens fitting for patients with keratoconus at the IKA Keratoconus Symposium in Scottsdale, Arizona.

John D. Gelles, OD, and Steven A. Greenstein, MD, share some insights into the new data on corneal cross-linking presented at IKA Keratoconus Symposium.

Today at the IKA Keratoconus Symposium, Justin Schweitzer, OD, FAAO, presented on establishing the keratoconus diagnosis alongside Kourtney Houser, MD.

President and CEO of the International Keratoconus Academy Andrew Morgenstern, OD, FAAO, FNAP, shares some snippets about the live white paper development session and the patient Q&A happening at the inaugural IKA Keratoconus Symposium.

Co-founder of the International Keratoconus Academy S. Barry Eiden, OD, FAAO, FSLS, gives us the inside scoop on the inaugural IKA Keratoconus Symposium, which takes place this weekend in Scottsdale, Arizona.

Uri Soiberman, MD, shares some key takeaways from his presentation at the inaugural IKA Keratoconus Symposium.

The results showed that current smokers had a greater 5-year cumulative probability, compared with patients who had never smoked, of undergoing orbital decompression, strabismus surgery, and eyelid recession.

According to the company, KPI-012 could become the first approved treatment for persistent corneal epithelial defect across all its various etiologies.

The authors conducted a prospective non-interventional study in which a self-questionnaire was used to evaluate the ocular symptoms and medical background of patients with KC and OSD who engage in chronic eye rubbing.